Workflow
线下药店
icon
Search documents
益丰药房跌2.15%,成交额3457.45万元,主力资金净流入6.14万元
Xin Lang Zheng Quan· 2025-10-09 02:01
10月9日,益丰药房盘中下跌2.15%,截至09:54,报24.12元/股,成交3457.45万元,换手率0.12%,总市 值292.44亿元。 截至6月30日,益丰药房股东户数2.16万,较上期增加7.70%;人均流通股56081股,较上期减少7.15%。 2025年1月-6月,益丰药房实现营业收入117.22亿元,同比减少0.35%;归母净利润8.80亿元,同比增长 10.32%。 分红方面,益丰药房A股上市后累计派现28.52亿元。近三年,累计派现19.46亿元。 机构持仓方面,截止2025年6月30日,益丰药房十大流通股东中,香港中央结算有限公司位居第二大流 通股东,持股2.37亿股,相比上期减少3538.96万股。南方中证500ETF(510500)位居第七大流通股 东,持股898.58万股,相比上期增加120.57万股。中欧医疗健康混合A(003095)位居第八大流通股 东,持股771.18万股,相比上期减少694.51万股。 责任编辑:小浪快报 资金流向方面,主力资金净流入6.14万元,大单买入274.53万元,占比7.94%,卖出268.39万元,占比 7.76%。 益丰药房今年以来股价涨2. ...
华人健康跌0.86%,成交额4027.14万元,近3日主力净流入-1036.09万
Xin Lang Cai Jing· 2025-09-30 09:05
来源:新浪证券-红岸工作室 9月30日,华人健康跌0.86%,成交额4027.14万元,换手率2.12%,总市值50.64亿元。 异动分析 医药电商+医疗器械概念+养老概念+阿里巴巴概念+创新药 1、据2023年2月17日互动易回复:公司除阿里旗下的天猫/饿了么平台外,公司在京东/拼多多/美团等国 内主要电商平台也都有布局,并且报告期内取得了长足发展。 2、安徽华人健康医药股份有限公司的主营业务是从事医药零售、代理及终端集采业务。公司的主要产 品是中成西药、中药饮片、保健品、医疗器械、特色原料。 资金分析 今日主力净流入-224.28万,占比0.06%,行业排名14/32,该股当前无连续增减仓现象,主力趋势不明 显;所属行业主力净流入-2.48亿,连续3日被主力资金减仓。 区间今日近3日近5日近10日近20日主力净流入-224.28万-1036.09万-301.80万-4945.41万-8468.28万 主力持仓 主力没有控盘,筹码分布非常分散,主力成交额2042.28万,占总成交额的2.04%。 技术面:筹码平均交易成本为14.02元 该股筹码平均交易成本为14.02元,近期该股有吸筹现象,但吸筹力度不强; ...
华人健康跌1.01%,成交额4249.06万元,后市是否有机会?
Xin Lang Cai Jing· 2025-09-26 08:06
Core Viewpoint - The company, Anhui Huaren Health Pharmaceutical Co., Ltd., is actively expanding its presence in the health sector, particularly focusing on elderly care and innovative pharmaceutical products, while facing fluctuations in stock performance and market interest [2][3][8]. Company Overview - Anhui Huaren Health Pharmaceutical Co., Ltd. was established on June 29, 2001, and listed on March 1, 2023. The company primarily engages in pharmaceutical agency, retail, and terminal procurement, with its main revenue derived from traditional Chinese and Western medicine, accounting for 97.60% of total revenue [7]. - The company is located in Hefei, Anhui Province, and operates within the pharmaceutical and biological industry, specifically in the pharmaceutical commercial sector, focusing on offline pharmacies [7]. Business Strategy - The company is strategically positioning itself in the silver-haired health sector by providing chronic disease training and services through pharmacies, aiming to enhance health management for the elderly [2]. - It is developing a series of products targeting common diseases among the elderly, including the "Fuman Medical" series for cardiovascular health and the "Guojin" series of traditional Chinese medicine for health maintenance [2][3]. Financial Performance - For the first half of 2025, the company reported a revenue of 2.504 billion yuan, representing a year-on-year growth of 15.52%, and a net profit attributable to shareholders of 104 million yuan, up 42.17% from the previous year [8]. - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [8]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 45.15% to 26,100, with an average of 5,725 shares held per person, a decrease of 31.10% [8]. - Alibaba Health is the second-largest shareholder, holding 7.51% of the company, and there are collaborations with various Alibaba platforms [3][8]. Market Activity - On September 26, the company's stock price fell by 1.01%, with a trading volume of 42.49 million yuan and a market capitalization of 5.08 billion yuan [1]. - The stock has shown no clear trend in major net inflows, with a net outflow of 8.27 million yuan on the day [4][5].
华人健康跌0.39%,成交额5773.75万元,近5日主力净流入-1320.10万
Xin Lang Cai Jing· 2025-09-25 07:53
Core Viewpoint - Anhui Huaren Health Pharmaceutical Co., Ltd. is actively expanding its presence in the senior health sector, focusing on chronic disease management and developing products tailored for elderly health needs [2][3]. Company Overview - Anhui Huaren Health Pharmaceutical Co., Ltd. was established on June 29, 2001, and went public on March 1, 2023. The company is primarily engaged in pharmaceutical agency, retail, and terminal procurement, with its main revenue derived from traditional Chinese and Western medicine, accounting for 97.60% of total revenue [7]. - As of June 30, 2023, the company had 26,100 shareholders, an increase of 45.15% from the previous period, with an average of 5,725 circulating shares per person, a decrease of 31.10% [8]. Financial Performance - For the first half of 2023, the company achieved a revenue of 2.504 billion yuan, representing a year-on-year growth of 15.52%. The net profit attributable to shareholders was 104 million yuan, up 42.17% year-on-year [8]. - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [8]. Market Position and Shareholder Structure - The company has a market capitalization of 5.132 billion yuan, with a trading volume of 57.7375 million yuan and a turnover rate of 3.00% on September 25, 2023 [1]. - Alibaba Health is the second-largest shareholder, holding 7.51% of the company, and there are collaborations with various Alibaba platforms [3]. Strategic Initiatives - The company is focusing on the senior health market by providing chronic disease training and services through pharmacies, enhancing health consultation and medication guidance for the elderly [2]. - It is developing a series of products aimed at common diseases in the elderly, including the "Fuman Medical" series for cardiovascular health and the "Guojin" series of traditional Chinese medicine health products [2][3].
益丰药房跌2.02%,成交额7322.79万元,主力资金净流入75.46万元
Xin Lang Cai Jing· 2025-09-25 03:09
Core Viewpoint - Yifeng Pharmacy's stock price has shown fluctuations, with a year-to-date increase of 5.76% but a recent decline of 2.67% over the past five trading days [2] Financial Performance - For the first half of 2025, Yifeng Pharmacy reported operating revenue of 11.722 billion yuan, a year-on-year decrease of 0.35%, while net profit attributable to shareholders increased by 10.32% to 880 million yuan [2] - Cumulative cash dividends since the company's A-share listing amount to 2.852 billion yuan, with 1.946 billion yuan distributed over the past three years [3] Stock Market Activity - As of September 25, Yifeng Pharmacy's stock price was 24.78 yuan per share, with a market capitalization of 30.044 billion yuan [1] - The stock experienced a trading volume of 73.2279 million yuan and a turnover rate of 0.24% on the same day [1] - The net inflow of main funds was 754,600 yuan, with significant buying and selling activity from large orders [1] Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 7.70% to 21,600, with an average of 56,081 circulating shares per shareholder, a decrease of 7.15% [2] - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 237 million shares, a decrease of 35.3896 million shares from the previous period [3]
健之佳跌2.05%,成交额1205.59万元,主力资金净流出62.31万元
Xin Lang Cai Jing· 2025-09-23 02:17
9月23日,健之佳盘中下跌2.05%,截至09:59,报20.59元/股,成交1205.59万元,换手率0.38%,总市值 31.82亿元。 截至6月30日,健之佳股东户数1.51万,较上期减少12.99%;人均流通股10236股,较上期增加26.21%。 2025年1月-6月,健之佳实现营业收入44.57亿元,同比减少0.64%;归母净利润7237.82万元,同比增长 15.11%。 资料显示,健之佳医药连锁集团股份有限公司位于云南省昆明市盘龙区联盟街道旗营街10号,成立日期 2004年9月27日,上市日期2020年12月1日,公司主营业务涉及药品、保健食品、个人护理品、家庭健康 用品、便利食品、日用消耗品等健康产品的连锁零售业务,并提供相关专业服务。主营业务收入构成 为:处方、非处方合计(中西成药)72.60%,其中:非处方药39.64%,其中:处方药32.96%,医疗器械 7.44%,其他(补充)5.52%,生活便利品5.05%,保健食品4.84%,中药材3.28%,个人护理品1.18%,体 检服务0.09%。 (000727)位居第五大流通股东,持股710.00万股,相比上期减少29.48万股。广发创 ...
华人健康跌0.54%,成交额4335.82万元,今日主力净流入-200.51万
Xin Lang Cai Jing· 2025-09-22 07:27
Core Viewpoint - The company, Anhui Huaren Health Pharmaceutical Co., Ltd., is experiencing a decline in stock price and trading volume, indicating potential challenges in the market despite its growth in revenue and profit [1][4]. Group 1: Company Overview - Anhui Huaren Health Pharmaceutical Co., Ltd. was established on June 29, 2001, and listed on March 1, 2023. Its main business involves pharmaceutical agency, retail, and terminal procurement [7]. - The company's revenue composition is primarily from traditional Chinese and Western medicine, accounting for 97.60%, with other products making up 2.40% [7]. - As of June 30, 2023, the company had 26,100 shareholders, an increase of 45.15% from the previous period, with an average of 5,725 circulating shares per person, a decrease of 31.10% [8]. Group 2: Financial Performance - For the first half of 2023, the company achieved a revenue of 2.504 billion yuan, representing a year-on-year growth of 15.52%. The net profit attributable to shareholders was 104 million yuan, up 42.17% year-on-year [8]. - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [8]. Group 3: Market Position and Trends - The company is actively expanding its presence on major e-commerce platforms, including JD.com, Pinduoduo, and Meituan, in addition to Alibaba's Tmall and Ele.me [2]. - The company is focusing on the integration of artificial intelligence in its operations, enhancing service efficiency and customer experience through AI medical consultations and customer service [2][3]. - As of June 30, 2023, the company is developing 22 research drugs, focusing on traditional Chinese medicine and high-end generic drugs [3]. Group 4: Stock Performance and Trading Activity - On September 22, 2023, the company's stock price fell by 0.54%, with a trading volume of 43.3582 million yuan and a turnover rate of 2.24%, resulting in a total market capitalization of 5.184 billion yuan [1]. - The stock has seen a net outflow of 2.0051 million yuan from major investors, indicating a reduction in holdings over the past three days [4][5]. - The average trading cost of the stock is 14.27 yuan, with the current price approaching a support level of 12.67 yuan, suggesting potential volatility if this support is breached [6].
大参林跌2.02%,成交额7853.97万元,主力资金净流出325.02万元
Xin Lang Cai Jing· 2025-09-22 06:05
Company Overview - Dazhonglin Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, established on February 12, 1999, and listed on July 31, 2017 [2] - The company's main business includes retail of traditional Chinese and Western medicines, health products, medical devices, and other goods, with revenue composition as follows: Western and Chinese medicines 76.88%, non-pharmaceuticals 10.49%, Chinese medicinal materials 9.75%, and others 2.88% [2] Financial Performance - For the first half of 2025, Dazhonglin achieved operating revenue of 13.523 billion yuan, a year-on-year increase of 1.33%, and a net profit attributable to shareholders of 798 million yuan, a year-on-year increase of 21.38% [2] - Since its A-share listing, Dazhonglin has distributed a total of 3.355 billion yuan in dividends, with 1.624 billion yuan distributed in the last three years [3] Stock Performance - As of September 22, Dazhonglin's stock price decreased by 2.02% to 16.99 yuan per share, with a total market capitalization of 19.349 billion yuan [1] - Year-to-date, the stock price has increased by 15.19%, with a decline of 1.74% over the last five trading days and a 0.70% decline over the last 20 days [2] - The stock has seen a 4.23% increase over the last 60 days [2] Shareholder Information - As of June 30, 2025, the number of shareholders is 31,500, a decrease of 10.07% from the previous period, with an average of 36,097 circulating shares per person, an increase of 11.20% [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 90.448 million shares, an increase of 12.4318 million shares from the previous period [3] Market Activity - On September 22, the net outflow of main funds was 3.2502 million yuan, with large orders buying 4.3386 million yuan (5.52% of total) and selling 7.5887 million yuan (9.66% of total) [1]
益丰药房跌2.02%,成交额6051.12万元,主力资金净流出362.48万元
Xin Lang Cai Jing· 2025-09-22 03:14
Core Viewpoint - Yifeng Pharmacy's stock has experienced fluctuations, with a recent decline of 2.02% and a year-to-date increase of 5.46%, indicating mixed market sentiment towards the company [1][2]. Financial Performance - For the first half of 2025, Yifeng Pharmacy reported a revenue of 11.722 billion yuan, a slight decrease of 0.35% year-on-year, while the net profit attributable to shareholders was 880 million yuan, reflecting a growth of 10.32% [2]. - Cumulatively, since its A-share listing, Yifeng Pharmacy has distributed a total of 2.852 billion yuan in dividends, with 1.946 billion yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 7.70% to 21,600, while the average circulating shares per person decreased by 7.15% to 56,081 shares [2]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 237 million shares, which is a decrease of approximately 35.39 million shares from the previous period [3]. Market Activity - On September 22, Yifeng Pharmacy's stock price was 24.71 yuan per share, with a trading volume of 60.51 million yuan and a turnover rate of 0.20% [1]. - The stock has seen a net outflow of 3.6248 million yuan in principal funds, with large orders accounting for 11.09% of purchases and 17.08% of sales [1].
老百姓涨2.04%,成交额2.00亿元,主力资金净流出2328.15万元
Xin Lang Zheng Quan· 2025-09-18 05:20
Core Viewpoint - The stock price of Lao Bai Xing has shown fluctuations, with a year-to-date increase of 7.24% but a significant decline over the past 60 days, indicating potential volatility in the market [2]. Company Overview - Lao Bai Xing Pharmacy Chain Co., Ltd. is located in Changsha, Hunan Province, established on December 1, 2005, and listed on April 23, 2015. The company primarily engages in the retail chain business of pharmaceuticals and health-related products [2]. - The revenue composition of the company includes 80.95% from Western and Chinese medicines, 12.11% from non-pharmaceutical products, and 6.94% from traditional Chinese medicine [2]. - As of June 30, 2025, the number of shareholders is 43,600, a decrease of 9.16% from the previous period, with an average of 17,396 circulating shares per shareholder, an increase of 10.08% [2]. Financial Performance - For the first half of 2025, Lao Bai Xing reported a revenue of 10.774 billion yuan, a year-on-year decrease of 1.51%, and a net profit attributable to shareholders of 398 million yuan, down 20.86% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 2.069 billion yuan in dividends, with 991 million yuan distributed over the past three years [3]. Shareholding Structure - As of June 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited as the third-largest shareholder with 15.0804 million shares, a decrease of 3.0999 million shares from the previous period. New entrants include Southern CSI 1000 ETF and Guotai Medical Health Stock A [3].